Blog16th July 2026CEO summer review 2026: advancing translational research through physiologically relevant iPSC‑derived models
News9th June 2026CellVoyant and Axol Bioscience partner to advance AI-guided imaging for cardiomyocyte manufacturing
Blog16th March 2026Patient stratification in Alzheimer’s disease: supporting preclinical in vitro model building and drug discovery with iPSCs
News31st March 2026PRISM ALS: New stem cell models could transform research into treatments for MND/ALS
News4th March 2026Axol Bioscience joins quantum biotechnology consortium advancing Alzheimer’s research
Blog3rd March 2026Microglia FAQ: applications, disease modeling, organoids, co‑cultures, screening & next‑gen advances
Blog23rd December 2025CEO end-of-year review 2025: building better human disease models for a changing world
News17th March 2025New MyoMaxTM Media Enhances iPSC-Derived Cardiomyocyte Maturity for Superior In Vitro Cardiac Models
News24th June 2025ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research
